Europe
The technique allows scientists to decipher how the cells in tumors are communicating with each other.
The company will be helmed by Jes Olesen, the former president of the European Federation of Neurological Societies and chairman of the Danish Headache Center.
The U.S. Food and Drug Administration accepted the companies’ New Drug Application for lurbinectedin under Priority Review.
Parkinson’s disease affects the brain’s nerve cells that produce dopamine. Researchers at the University of Helsinki have identified a molecule called BT13 that potentially can increase levels of dopamine.
It was a very busy week for clinical trial news. Here’s a look.
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
There is a significant amount of work being done on cardiovascular diseases. Here’s a look at just some of the recent news.
Biopharma and life sciences companies bolster their leadership teams and board with this week’s Movers & Shakers.
Are you in the United Kingdom and looking for a job in the life sciences? Or, are you planning on having a career in the life sciences? If so, then, you’ll be happy to know that there are an expected 133,000 jobs to be added to the sector over the next 10 years.
Ipsen’s decision to pause dosing in its studies of palovarotene trials for patients with fibrodysplasia ossificans progressive (FOP) has hit the France-based company right in the pocketbook.
PRESS RELEASES